Imunon, Inc. will hold a conference call on May 12, 2026, to report its first quarter financial results and update investors on the clinical development of IMNN-001, its DNA-based immunotherapy for advanced ovarian cancer. The company is advancing Phase 3 trials of IMNN-001, which aims to boost cancer-fighting molecules at tumor sites. This update follows successful Phase 2 trials showing improved survival rates, positioning IMNN-001 as a promising treatment option. Investors can join the call via phone or webcast to learn more about the company’s progress and future plans.
Ichor Holdings, a semiconductor equipment supply chain company, reported a 24% year-over-year revenue increase to $294.8 million in Q2 2026, driven by recovering demand in semiconductor equipment. The company also improved its non-GAAP gross margin t...
Ethereum has recently surged past $2,500, approaching a technical pattern called a golden cross, where a short-term moving average crosses above a long-term one, often signaling a bullish trend. However, Ethereum's momentum is currently weak, with re...
Bitwise reported about $100 million in net inflows on August 27 across its U.S. crypto exchange-traded products, with Solana funds leading at roughly $40 million, followed by Bitcoin at $22 million and Hyperliquid at $20 million. The Solana Staking E...
MINISO Group reported a 22.4% year-on-year revenue increase to RMB 11.5 billion in the first half of 2026, led by a 26.2% growth in Chinese mainland sales and a 37.0% rise in North America. The company expanded its store network by 769 stores year-ov...
Precious metals prices rose on Friday, lifting shares of London-listed miners Endeavour Mining and Fresnillo on the FTSE 100. Endeavour Mining's stock increased by 2.26% and Fresnillo's by 1.83%, driven by gains in gold, silver, platinum, and palladi...
